aTYR PHARMA INC

ATYR · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
221
SEC Filings

Business Summary

PART I Item 1. Bu siness. We are a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. Our discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by our proprietary library of domains d...

Next Earnings

Q2 FY2026 — expected 2026-09-14

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionATYRdiscussed_in_filing Cybersecurity
topic_mentionATYRdiscussed_in_filing Cybersecurity
topic_mentionATYRdiscussed_in_filing Healthcare & Bio
topic_mentionATYRdiscussed_in_filing Platform & Ecosystem
topic_mentionATYRdiscussed_in_filing Healthcare & Bio
topic_mentionATYRdiscussed_in_filing Platform & Ecosystem

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-052025-12-310001339970-26-000008EDGAR79K words
2025-03-132024-12-310000950170-25-038888EDGAR—
2024-03-142023-12-310000950170-24-031584EDGAR—
2023-03-142022-12-310000950170-23-007873EDGAR—
2022-03-152021-12-310001564590-22-010441EDGAR—
2021-03-242020-12-310001564590-21-014940EDGAR—
2020-03-262019-12-310001564590-20-013208EDGAR—
2019-03-262018-12-310001564590-19-009381EDGAR—
2018-03-202017-12-310001564590-18-006333EDGAR—
2017-03-162016-12-310001564590-17-004631EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001193125-25-269587EDGAR53K words
2025-08-072025-06-300001339970-25-000009EDGAR—
2025-05-072025-03-310000950170-25-065640EDGAR—
2024-11-072024-09-300000950170-24-123305EDGAR—
2024-08-132024-06-300000950170-24-096185EDGAR—
2024-05-022024-03-310000950170-24-052092EDGAR—
2023-11-092023-09-300000950170-23-062058EDGAR—
2023-08-092023-06-300000950170-23-040598EDGAR—
2023-05-092023-03-310000950170-23-019686EDGAR—
2022-11-142022-09-300000950170-22-024724EDGAR—
2022-08-152022-06-300000950170-22-017401EDGAR—
2022-05-102022-03-310001564590-22-019293EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-050001339970-26-000006EDGAR3K words
2025-12-050001193125-25-309619EDGAR—
2025-11-060001193125-25-269486EDGAR—
2025-09-150001193125-25-202865EDGAR—
2025-08-070001339970-25-000007EDGAR—
2025-05-070000950170-25-065611EDGAR—
2025-05-060000950170-25-064413EDGAR—
2025-03-130000950170-25-038703EDGAR—
2024-12-230000950170-24-139633EDGAR—
2024-12-120000950170-24-135766EDGAR—

221 total filings indexed. 189 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001339970
TickerATYR
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: a6503ee2fdc6ca4d2774eeec5752492b8d2960e6d9f7c20b306f95bf8c04fa62
parent: 0191de74eb88fae24d52cf3b0455563a142829393096c331c9ce9dfe64299be1
content hash: 3f585317a4dcf34a652443ead9ce4ba215974f69c53ce17bc9f6a90742f043b6
signed: 2026-04-13T04:43:47.854Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf